Overview

Study of Pemetrexed in the Treatment of Patients With Ovarian Cancer Who Have Failed Prior Platinum-Based Chemotherapy

Status:
Completed
Trial end date:
2007-03-01
Target enrollment:
Participant gender:
Summary
The purposes of this study are to determine: - whether standard or higher doses of pemetrexed should be given to patients with ovarian or primary peritoneal cancer that has recurred; - the safety and side effects of standard and higher doses of pemetrexed given to patients with ovarian or primary peritoneal cancer that has recurred; - whether standard or higher doses of pemetrexed can help patients with ovarian or primary peritoneal cancer that has recurred.
Phase:
Phase 2
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Pemetrexed